TIGIT⁺ CD4⁺ regulatory T cells enhance PD-1 expression on CD8⁺ T cells and promote tumor growth in a murine ovarian cancer model.

ABSTRACT: Immune checkpoint-based immunotherapy has shown limited efficacy in the treatment of ovarian cancer. In recent years, the emergence of immune checkpoint co-targeting therapies, led by the combination targeting of TIGIT and FAK, has shown promise in ovarian cancer treatment. Our preliminary research indicates that TIGIT is predominantly expressed in regulatory T cells during ovarian cancer. However, the therapeutic impact of TIGIT targeting based on regulatory T cells in ovarian cancer remains to be elucidated. We utilized ID8 cells to establish a mouse model of ovarian cancer. Through flow cytometry and co-culture methods, we validated the relationship between the functionality of regulatory T cells and tumor masses, and confirmed the crucial role of TIGIT in immune suppression in ovarian

SUBMITTER: Chen F 

PROVIDER: S-EPMC11660701 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature